Posted by Michael Wonder on 30 Nov 2015
FDA approves Empliciti, a new immune-stimulating therapy to treat multiple myeloma
30 November 2015 - Today the U.S. FDA granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications.
For more details, go to: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474684.htm
